Tcr2 Therapeutics Inc (NASDAQ:TCRR) shot up 15.2% during trading on Thursday . The stock traded as high as $19.50 and last traded at $17.90, 150,580 shares changed hands during trading. An increase of 206% from the average session volume of 49,257 shares. The stock had previously closed at $15.54.
Several research firms have commented on TCRR. Zacks Investment Research upgraded shares of Tcr2 Therapeutics from a “sell” rating to a “hold” rating in a report on Friday, July 12th. Roth Capital began coverage on shares of Tcr2 Therapeutics in a report on Friday, May 31st. They set a “neutral” rating and a $16.00 price target for the company. Two research analysts have rated the stock with a hold rating and five have given a buy rating to the company. Tcr2 Therapeutics presently has a consensus rating of “Buy” and an average price target of $27.80.
The stock has a market cap of $372.03 million and a P/E ratio of -0.18. The business has a fifty day moving average of $13.93.
Hedge funds have recently added to or reduced their stakes in the stock. Laurion Capital Management LP purchased a new stake in Tcr2 Therapeutics in the 1st quarter valued at $417,000. Dean Capital Investments Management LLC purchased a new stake in Tcr2 Therapeutics in the 1st quarter valued at $694,000. Redmile Group LLC purchased a new stake in Tcr2 Therapeutics in the 1st quarter valued at $28,686,000. Finally, MPM Asset Management LLC purchased a new stake in Tcr2 Therapeutics in the 1st quarter valued at $67,192,000. Hedge funds and other institutional investors own 33.26% of the company’s stock.
Tcr2 Therapeutics Company Profile (NASDAQ:TCRR)
TCR2 Therapeutics Inc, a clinical-stage immunotherapy company, develops novel T cell receptor therapies for patients suffering from cancer. Its product candidates in pipeline comprise TC-210 mono TCR Fusion Construct T cells (TRuC-T cells) targeting mesothelin positive solid tumors; TC-220 that targets MUC16 positive solid tumors; and TC-310 and TC-410 dual TRuC-T cell programs targeting CD19/22 and MSLN/MUC16, as well as TC-110 mono TRuC-T cells targeting CD19-positive B-Cell hematological malignancies.
Receive News & Ratings for Tcr2 Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tcr2 Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.